Profiling of drug resistance in Src kinase at scale uncovers a regulatory network coupling autoinhibition and...

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Kinase inhibitors are vital cancer treatments, but drug resistance frequently limits their effectiveness.
• While many resistance mutations are known, the complete mechanisms of kinase inhibitor resistance remain unclear.
• Src tyrosine kinase is a key target in various cancers, and understanding its resistance is clinically relevant.

Purpose of the Study:

• To comprehensively profile resistance mutations in Src tyrosine kinase against ATP-competitive inhibitors.
• To identify novel mechanisms and pathways driving drug resistance in kinase inhibitors.
• To explore the regulatory roles of specific residue clusters in kinase activity and drug response.

Main Methods:

• Systematic profiling of approximately 3,500 Src tyrosine kinase mutants against four distinct ATP-competitive inhibitors.
• Analysis of mutation distribution within the catalytic domain and their impact on inhibitor binding.
• Investigation of residue clusters involved in kinase autoinhibition and their role in resistance.

Main Results:

• Resistance mutations are distributed across Src's catalytic domain, affecting both inhibitor contact sites and regulatory residues.
• A novel cluster of residues on the N-terminal lobe was identified as crucial for autoinhibition and prone to resistance mutations.
• Mutations in this cluster lower inhibitor affinity and promote kinase hyperactivation, leading to drug resistance.

Conclusions:

• Drug resistance profiling can elucidate potential resistance pathways and uncover new kinase regulatory mechanisms.
• Understanding the dynamics and regulatory roles of specific residue clusters is key to overcoming kinase inhibitor resistance.
• This study provides insights into Src kinase regulation and offers strategies for developing more effective cancer therapies.